1. Scrip

AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist

Positive Clinical Update On Evusheld

 
• By Kevin Grogan

AstraZeneca has presented more promising data from the PROVENT trial of its antibody combination therapy Evusheld which shows high levels of protection from COVID-19 for at least six months.

AstraZeneca
• Source: Shutterstock: Elzbieta Krzysztof

AstraZeneca PLC will be hoping that more impressive data on Evusheld, its antibody cocktail for the prevention of COVID-19, will boost sales of the combo which has key approvals on both sides of the Atlantic but is being plagued with access issues.

The drug major has presented detailed results from the 5,197-patient PROVENT Phase III pre-exposure prophylaxis trial, which formed the basis of approvals in the USA and EU, that show Evusheld (tixagevimab/cilgavimab) reduced the risk of developing symptomatic COVID-19

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.